Before he co-founded Provention Bio, Ashleigh Palmer worked on inhaled nitric oxide for infants with respiratory failure. After the company was sold for $1.2 billion to a Baxter-led consortium, Palmer noticed there was apprehension about conducting clinical trials with neonates. He was concerned that the inhaled NO assets were slated to fall to the wayside.
“I had seen blue babies turn pink,” Palmer told Drug Delivery Business News. He went on to spin out the technology into a new company, INO Therapeutics.
“What I saw was the industry’s propensity to avoid unusual drugs, unusual therapies, things that are outside of the box,” he said. “That vision has always stayed with me. What else is out there that is being under-developed?”